Movers and SHAKERS
Business Update: Positive Trajectory Continues
Noble Capital Markets research on Ceapro is published under ticker symbols (CRPOF and CZO:CA). The price target is in USD and based on ticker symbol CRPOF. Ceapro Inc is engaged in the development and application of proprietary extraction technology to produce extracts and active ingredients from oats and other renewable plant sources. Its operating segments are the Active ingredient product technology industry and the Cosmeceutical industry. The company derives a majority of the revenue from the Active ingredient product technology industry segment which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Geographically, the company has business operations in the U.S, Germany, China, Canada and other countries.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Noblecon presentation. Ceapro is going to present, during Noble’s annual conference Noblecon17 at 11:15 AM ET on January 20th, 2021.
Broad applicability of the technology and the pipeline. We think Ceapro’s PGX platform technology and pipeline has the capability to produce novel products in nutraceutical and cosmeceutical, and also in the biopharmaceutical market including Covid-19. We foresee value expansion upon clinical advancement, data, and revenue growth from its pipeline products ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.